This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

EZN-3042

Roche Holding AG

Drug Names(s): SPC3042

Description: SPC3042 is a LNA-antisense compound against survivin mRNA.

Deal Structure: Enzon and Santaris
In July 2006, Enzon and Santaris Pharma announced that the companies have enteredinto a collaboration to co-develop and commercialize a series of RNA Antagonists based on Santaris Pharma's LNA (locked nucleic acid) technology and utilizing Enzon's oncology drug development expertise.

Under the terms of the agreement, Enzon is licensing two ofSantaris Pharma's preclinical development compounds, including its Survivin antagonist (SPC3042). Enzon will have exclusive rights to develop and commercialize these compounds in theU.S. and other non-European territories. Santaris will retain exclusive rights to commercialization in Europe. The companies willshare development data for use in their respective territories.

Enzon will make an initial up-front payment of $8 million to Santaris Pharma, followed by an additional $3 million upon the successful identification of certain LNA targets and additional payments on the achievement of pre-specified...See full deal structure in Biomedtracker


EZN-3042 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug